Home › Leucemia mieloide acuta › Michigan › Detroit
Studi clinici su Leucemia mieloide acuta a Detroit, MI
14 studi su Leucemia mieloide acuta cercano partecipanti presso sedi a Detroit e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
In reclutamentoFase 2
- Wayne State University/Karmanos Cancer Institute, Detroit
- Henry Ford Hospital, Detroit
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
In reclutamentoStudio osservazionaleVolontari sani benvenuti
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
In reclutamentoFase 3
- Henry Ford Health System, Detroit
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
In reclutamentoFase 2
- Henry Ford Hospital, Detroit
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
In reclutamentoFase 2
- Wayne State University/Karmanos Cancer Institute, Detroit
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
In reclutamentoFase 1/2
- Children's Hospital of Michigan, Detroit
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
In reclutamentoFase 3
- Children's Hospital of Michigan, Detroit
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
In reclutamentoFase 3
- Wayne State University School of Medicine, Detroit
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
In reclutamentoFase 1
- Karmanos Cancer Institute, Detroit
- Henry Ford Cancer Institute, Detroit
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
In reclutamentoFase 3
- Henry Ford Cancer Institute, Detroit
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
In reclutamentoStudio osservazionale
- Children's Hospital of Michigan, Detroit
- Henry Ford Health System, Detroit
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
In reclutamentoFase 2
- Karmanos Cancer Institute, Detroit
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
In reclutamentoFase 1
- Karmanos Cancer Institute, Detroit
HPC Offered for PRESERVE Expansion
In reclutamentoStudio osservazionale
- Henry Ford Health, Detroit
Studi su Leucemia mieloide acuta in altre città
- Houston, TX85 studi
- New York City, NY51 studi
- Boston, MA44 studi
- Seattle, WA41 studi
- Baldwin Park, CA40 studi
- Columbus, OH35 studi
- Philadelphia, PA34 studi
- Durham, NC33 studi
- Atlanta, GA31 studi
- Tampa, FL29 studi
- Chicago, IL26 studi
- Portland, OR25 studi
Altri studi a Detroit
- Cancro del polmone non a piccole cellule44 studi
- Cancro al seno33 studi
- Cancro (tutti i tipi)29 studi
- Cancro colorettale26 studi
- Cancro ovarico26 studi
- Cancro metastatico24 studi
- Cancro alla prostata22 studi
- Cancro dell'endometrio21 studi
- Cancro ai polmoni20 studi
- Mieloma multiplo19 studi
- Cancro dello stomaco16 studi
- Carcinoma a cellule squamose della testa e del collo15 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.